CY1111597T1 - Παραγωγα φθαλαζινονης - Google Patents

Παραγωγα φθαλαζινονης

Info

Publication number
CY1111597T1
CY1111597T1 CY20111100619T CY111100619T CY1111597T1 CY 1111597 T1 CY1111597 T1 CY 1111597T1 CY 20111100619 T CY20111100619 T CY 20111100619T CY 111100619 T CY111100619 T CY 111100619T CY 1111597 T1 CY1111597 T1 CY 1111597T1
Authority
CY
Cyprus
Prior art keywords
crxry
optionally substituted
nrx
aromatic ring
fused aromatic
Prior art date
Application number
CY20111100619T
Other languages
Greek (el)
English (en)
Inventor
Niall Morrison Barr Martin
Graeme Cameron Murray Smith
Stephen Philip Jackson
Vincent Junior M Loh
Xiao-Ling Fan Cockcroft
Ian Timothy Williams Matthews
Keith Allan Menear
Frank Kerrigan
Alan Ashworth
Original Assignee
Kudos Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32996122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111597(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0305681.9A external-priority patent/GB0305681D0/en
Application filed by Kudos Pharmaceuticals Limited filed Critical Kudos Pharmaceuticals Limited
Publication of CY1111597T1 publication Critical patent/CY1111597T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CY20111100619T 2003-03-12 2011-06-28 Παραγωγα φθαλαζινονης CY1111597T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0305681.9A GB0305681D0 (en) 2003-03-12 2003-03-12 Phthalazinone derivatives
US45499503P 2003-03-14 2003-03-14
US49339903P 2003-08-06 2003-08-06
US52624403P 2003-12-01 2003-12-01
EP04720068A EP1633724B1 (en) 2003-03-12 2004-03-12 Phthalazinone derivatives

Publications (1)

Publication Number Publication Date
CY1111597T1 true CY1111597T1 (el) 2015-10-07

Family

ID=32996122

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100619T CY1111597T1 (el) 2003-03-12 2011-06-28 Παραγωγα φθαλαζινονης

Country Status (21)

Country Link
EP (1) EP1633724B1 (enExample)
JP (3) JP4027406B2 (enExample)
KR (1) KR101146806B1 (enExample)
AU (1) AU2004220321B2 (enExample)
BR (1) BRPI0408284B8 (enExample)
CA (1) CA2517629C (enExample)
CO (1) CO5650256A2 (enExample)
CY (1) CY1111597T1 (enExample)
EA (1) EA009469B1 (enExample)
EC (1) ECSP056094A (enExample)
GB (1) GB2415430B (enExample)
HR (1) HRP20050895B1 (enExample)
IS (1) IS2813B (enExample)
LT (1) LTC1633724I2 (enExample)
MA (1) MA27758A1 (enExample)
MX (1) MXPA05009661A (enExample)
NO (2) NO331807B1 (enExample)
NZ (1) NZ542680A (enExample)
PL (1) PL1633724T3 (enExample)
TN (1) TNSN05212A1 (enExample)
WO (1) WO2004080976A1 (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
EP1651620B1 (en) 2003-07-30 2011-11-09 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US20070104709A1 (en) 2003-08-06 2007-05-10 Xiaodong Li T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
DK2305221T3 (en) * 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
WO2006021801A1 (en) * 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
EP1645556A1 (en) * 2004-10-07 2006-04-12 Boehringer Ingelheim International GmbH Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
SG159528A1 (en) * 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
WO2007035010A2 (en) 2005-09-23 2007-03-29 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
WO2007144637A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage
AU2013201880B2 (en) * 2006-10-17 2015-06-25 Kudos Pharmaceuticals Limited Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
PH12012501544A1 (en) 2006-12-28 2024-06-03 Abbvie Inc Inhibitors of poly (adp-ribose) polymerase
WO2008146035A1 (en) * 2007-05-25 2008-12-04 Astrazeneca Ab Combination of chk and parp inhibitors for the treatment of cancers
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
GB0716532D0 (en) * 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102083314B (zh) 2007-10-03 2014-04-30 卫材股份有限公司 Parp抑制剂化合物、组合物以及使用方法
RU2487868C2 (ru) * 2007-10-17 2013-07-20 Кудос Фармасеутикалс Лимитед 4-[3-(4-циклопропанкарбонил-пиперазин-1-карбонил)-4-фтор-бензил]-2н-фталазин-1-он
KR101641596B1 (ko) 2007-11-15 2016-07-21 엠에스디 이탈리아 에스.알.엘. Ｐａｒｐ 억제제로서의 피리다지논 유도체
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
CA2708364A1 (en) 2007-12-11 2009-06-18 Efrat Ben-Zeev Carboxamide compounds and their use as chemokine receptor agonists
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
WO2010017055A2 (en) 2008-08-06 2010-02-11 Lead Therapeutics, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
NZ592719A (en) * 2008-10-07 2012-09-28 Astrazeneca Uk Ltd PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
CN103724328B (zh) 2008-12-19 2015-10-14 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) * 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
AR083502A1 (es) * 2010-10-21 2013-02-27 Biomarin Pharm Inc Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina
ES2590682T3 (es) * 2010-12-02 2016-11-23 Shanghai De Novo Pharmatech Co Ltd. Derivados heterocíclicos, procesos de preparación y usos médicos de los mismos
US9090568B2 (en) * 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
CA2833914A1 (en) * 2011-05-10 2012-11-15 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
CN103827314A (zh) 2011-05-18 2014-05-28 国家科学研究中心 用于诊断癌侵袭性和遗传不稳定性的标记
ES2871052T3 (es) * 2011-05-31 2021-10-28 Rakovina Therapeutics Inc Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
EP2800821B1 (en) 2012-01-05 2016-11-16 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of lung cancer aggressiveness
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
MA38080A1 (fr) 2012-12-31 2018-02-28 Cadila Healthcare Ltd Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
MX359656B (es) * 2013-07-31 2018-10-05 Merck Patent Gmbh Derivados de oxoquinazolinil-butanamida.
WO2015018475A1 (en) * 2013-08-07 2015-02-12 Merck Patent Gmbh Piperidine urea derivatives
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105985294B (zh) * 2015-02-11 2020-12-25 四川科伦药物研究院有限公司 一种奥拉帕尼的制备方法
EP3280708B1 (en) 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
JP6789239B2 (ja) 2015-04-15 2020-11-25 アラクセス ファーマ エルエルシー Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
US10857140B2 (en) * 2015-05-06 2020-12-08 The Regents Of The University Of California K-Ras modulators
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
DK3325662T3 (da) 2015-07-17 2023-11-27 Pacylex Pharmaceuticals Inc Epigenetisk inaktivering af nmt2
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CN106554316B (zh) * 2015-09-28 2019-03-08 上海医药集团股份有限公司 一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EA038635B9 (ru) 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
KR20180113976A (ko) 2015-11-20 2018-10-17 센화 바이오사이언시즈 인코포레이티드 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017191562A1 (en) * 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
US11072600B2 (en) 2016-06-24 2021-07-27 The Regents Of The University Of California Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018038680A1 (en) * 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
CN107955001A (zh) * 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018255413A1 (en) 2017-04-20 2019-12-05 Leidos Biomedical Research, Inc. K-Ras modulators
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
JP2021516229A (ja) * 2018-02-28 2021-07-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤
JP7534218B2 (ja) 2018-03-13 2024-08-14 ヴァレリオ・セラピューティクス がんの治療における獲得耐性に対抗するｄｂａｉｔ分子
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019222272A1 (en) * 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN108558773A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种奥拉帕尼药物中间体的制备方法
EP3829580A1 (en) 2018-08-01 2021-06-09 Araxes Pharma LLC Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020232119A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114144413B (zh) 2019-07-19 2024-08-16 阿斯利康(瑞典)有限公司 Parp1抑制剂
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4087563A4 (en) * 2020-01-07 2024-03-27 Shanghai Huayu Biotechnology Co., Ltd. CANCER COMBINATION THERAPY USING A CHK INHIBITOR
JP2023509191A (ja) 2020-01-09 2023-03-07 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4112049A4 (en) * 2020-02-24 2024-07-24 Fukang (Shanghai) Health Technology Co., Ltd. ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR
AU2020444056A1 (en) 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound
EP4139298A4 (en) 2020-04-21 2024-05-22 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
AU2021262569A1 (en) 2020-04-28 2022-11-24 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
CN111592522B (zh) * 2020-06-17 2022-09-09 郑州大学 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
WO2022058785A1 (en) 2020-09-16 2022-03-24 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
TW202222350A (zh) 2020-10-09 2022-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及parp1選擇性抑制劑之組合
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN112500379B (zh) * 2020-12-23 2024-01-23 南京方生和医药科技有限公司 一种奥拉帕利中间体及奥拉帕利的制备方法
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
WO2022245131A1 (ko) 2021-05-18 2022-11-24 온코닉 테라퓨틱스 주식회사 Parp 저해제 저항성 암 치료제
WO2022253800A1 (en) 2021-06-02 2022-12-08 Astrazeneca Ab Methods of treating breast cancer
EP4384501A4 (en) 2021-08-09 2025-01-22 Glenmark Life Sciences Limited Process for the preparation of olaparib, and crystalline form thereof
KR102645122B1 (ko) 2021-08-25 2024-03-07 주식회사 보령 올라파립의 제조방법
CN120309514A (zh) * 2021-09-15 2025-07-15 上海博邦医药科技有限公司 一种奥拉帕尼中间体的制备方法
US12049452B2 (en) 2021-11-10 2024-07-30 Nuformix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CA3242082A1 (en) 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
KR102776660B1 (ko) * 2022-01-25 2025-03-04 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도
KR20240148418A (ko) 2022-02-15 2024-10-11 아스트라제네카 아베 전립선암을 치료하는 방법
WO2024199668A1 (en) 2023-03-31 2024-10-03 Astrazeneca Ab Dosing regiment of azd5305
TW202515604A (zh) 2023-05-31 2025-04-16 瑞典商阿斯特捷利康公司 用於治療卵巢癌之方法、組成物和組合
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
CN119488588A (zh) 2023-08-17 2025-02-21 阿斯利康(瑞典)有限公司 用于治疗子宫内膜癌的方法、组合物和组合
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025153668A1 (en) 2024-01-19 2025-07-24 Astrazeneca Ab Pharmaceutical compositions comprising azd5305

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100804564B1 (ko) * 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
EP1397350B1 (en) * 2001-05-08 2007-02-28 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
ES2357057T3 (es) * 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
KR101146806B1 (ko) * 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체

Also Published As

Publication number Publication date
ECSP056094A (es) 2006-03-01
NO331807B1 (no) 2012-04-10
EA009469B1 (ru) 2007-12-28
JP4027406B2 (ja) 2007-12-26
TNSN05212A1 (en) 2007-06-11
JP4268651B2 (ja) 2009-05-27
CO5650256A2 (es) 2006-06-30
HRP20050895B1 (hr) 2014-06-06
KR101146806B1 (ko) 2012-05-22
GB0520754D0 (en) 2005-11-23
JP2009079056A (ja) 2009-04-16
WO2004080976A1 (en) 2004-09-23
NO20054625D0 (no) 2005-10-07
NZ542680A (en) 2008-08-29
CA2517629C (en) 2011-07-12
EP1633724A1 (en) 2006-03-15
LTC1633724I2 (lt) 2016-12-12
JP2008001718A (ja) 2008-01-10
PL1633724T3 (pl) 2011-10-31
NO20054625L (no) 2005-11-11
EP1633724B1 (en) 2011-05-04
AU2004220321B2 (en) 2010-02-25
WO2004080976A8 (en) 2006-01-05
CA2517629A1 (en) 2004-09-23
IS2813B (is) 2012-11-15
MXPA05009661A (es) 2006-03-08
HRP20050895A2 (hr) 2005-12-31
JP2006519827A (ja) 2006-08-31
IS8052A (is) 2005-09-28
GB2415430B (en) 2006-07-12
AU2004220321A1 (en) 2004-09-23
BRPI0408284A (pt) 2006-03-07
BRPI0408284B1 (pt) 2018-12-26
NO2015008I2 (no) 2015-03-12
GB2415430A (en) 2005-12-28
KR20060054172A (ko) 2006-05-22
BRPI0408284B8 (pt) 2021-05-25
EA200501434A1 (ru) 2006-02-24
HK1079530A1 (en) 2006-04-07
MA27758A1 (fr) 2006-02-01
NO2015008I1 (no) 2015-03-23

Similar Documents

Publication Publication Date Title
CY1111597T1 (el) Παραγωγα φθαλαζινονης
ATE508118T1 (de) Phthalazinonderivative
ECSP099813A (es) Derivados de ftalazinona
ATE247629T1 (de) N2-phenylamidine derivate
CY1108398T1 (el) Διαδικασια και ενδιαμεσα για την παραγωγη 7-υποκατεστημενων αντιοιστρογονων
CY1106237T1 (el) Ετepοκυκλικα παραγωγα με 5 μελη στο δακτυλιο και εφαρμογη αυτων ως παρεμποδιστων της μονοαμινο οξυδασης
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
CY1106346T1 (el) Μεθοδος για την παρασκευη της ενωσης clopidogrel
UA42684C2 (uk) Похідні бензимідазолону та їх фізіологічно прийнятні кислотно-адитивні солі
CY1105344T1 (el) Αμινουχα παραγωγα της διυδρο- 1,3,5 - τριαζινης και οι εφαρμογες τους στη θepαπευτικη
PT1064281E (pt) Derivados de distamicina benzo-heterociclicos processo para os preparar e a sua utilizacao como agentes antitumorais
CY1110377T1 (el) Ανδρογονα 7-υποκατεστημενα 11-αλογονουχα στεροειδη
WO2005011697A3 (en) Sulfonamide derivatives with activity on protein kinase a and b
HUP9700983A2 (hu) 1,4-Diaril-2-fluor-2-butén-származékok, intermedierjeik, előállításuk és alkalmazásuk, valamint hatóanyagként ezeket a vegyületeket tartalmazó inszekticid és akaricid készítmények
HUP0100210A1 (hu) 11 Béta-helyzetben szubsztituált új 19-nor-szteroidok, eljárás előállításukra, közbenső termékek és ilyen vegyületeket tartalmazó gyógyászati kompozíciók
CY1105422T1 (el) Νεα πιπepιδινυλο-αλκυλαμινο-πυριδαζινονικα παραγωγα, μια διαδικασια για την παρασκευη τους και φαρμακευτικες συνθεσεις οι οποιες πepιεχουν τις εν λογω ενωσεις
ATE370140T1 (de) Kondensierte bicyclische pyrimidinderivate
AU2001287996A1 (en) Process for the preparation of triphenodioxazine pigments
KR940014360A (ko) 1,4-벤즈옥사진 유도체
ATE257382T1 (de) 3-carboalkoxy-2,3-dihydro-1h-phenothiazin-4(10h - one derivate
GR21505B (el) Πολυμερη εξοχως κανονικης υφης και μεθοδος δια την παρασκευην των.
GB1040552A (en) New sulphur-containing quinoline derivatives
SE7703284L (sv) Framstellning av isoxazolo(3,4-d)pyrimidiner
HK1138006A (en) Phthalazinone derivatives as inhibitors of parp-1
PT1565479E (pt) Derivados 2'-o-silil trissubstituido-oximetil-ribonucleosido e metodo para a sua preparacao